• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • J&J's Imbruvica scores fifth FDA lymphoma approval pharmafile
    January 23, 2017
    Johnson & Johnson’s Imbruvica (ibrutinib) has scored its fifth indication approval in the US for the treatment of Marginal Zone Lymphoma (MZL), this time in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service